Search Results - "Demonty, G"

Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer—Gynaecological Cancer Group) by Witteveen, P.O., van der Velden, J., Vergote, I., Guerra, C., Scarabeli, C., Coens, C., Demonty, G., Reed, N.

“…No standard treatment options are available for patients with advanced, recurrent or metastatic vulvar carcinoma not amenable for locoregional treatment. In…”
Get full text

1029 Incidence of bone metastases in women with breast cancer: A meta-analysis of the published literature by Body, J.J, Taylor, A, Demonty, G, Talbot, S, Quinn, G, Booth, E, Amelio, J

Get full text

P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis by Sobrero, A, Douillard, J-Y, Rivera, F, get, F, Karthaus, M, Valladares-Ayerbes, M, Demonty, G, Guan, X, Peeters, M

Get full text

PD-031An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials by Rivera, F, Karthaus, M, Valladares-Ayerbes, M, Gallego, J, Koukakis, R, Demonty, G, Douillard, J-Y

Get full text

PD-026Survival outcomes in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) classified by Kohne prognostic category and BRAF mutation status: retrospective analysis of the PRIME study by Kohne, C-H, Rivera, F, Taieb, J, Siena, S, Peeters, M, Koukakis, R, Demonty, G, Douillard, J-Y

Get full text

PD-028Retrospective analysis of impact of Kohne prognostic category and BRAF mutation status on survival in patients with RAS wild-type metastatic colorectal cancer treated with second-line FOLFIRI with/without panitumumab by Peeters, M, Siena, S, Douillard, J-Y, Rivera, F, Taieb, J, Koukakis, R, Demonty, G, Kohne, C-H

Get full text

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC) by Rivera, F, Karthaus, M, Hecht, J.R, Fasola, G, Canon, J.L, Guan, X, Demonty, G, Schwartzberg, L.S

Get full text

2118 Quality of life (QoL) during second-line treatment with FOLFIRI +/- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC) by Sobrero, A.F, Price, T.J, Cervantes, A, Ducreux, M, Andre, T, Lordick, F, Punt, C.J, Hechmati, G, Demonty, G, Koukakis, R, Peeters, M

Get full text

2130 Tumour response outcomes during the first-line treatment of metastatic colorectal carcinoma (mCRC) with panitumumab + FOLFIRI by Karthaus, M, Hofheinz, R, Mineur, L, Letocha, H, Greil, R, Thaler, J, Fernebro, E, Zhang, Y, Oliner, K.S, Demonty, G, Kohne, C.H

Get full text

‘Pure’ invasive apocrine carcinoma of the breast: a new clinicopathological entity? by Japaze, H., Emina, J., Diaz, C., Schwam, R.J., Gercovich, N., Demonty, G., Morgenfeld, E., Rivarola, E., Gil Deza, E., Gercovich, F.G.

“…Invasive apocrine carcinoma (IAC) of the breast has a similar prognosis to infiltrating ductal carcinoma not otherwise specified (IDC-NOS). The existence of a…”
Get full text

Adjuvant chemotherapy in 2005: Standards and beyond by Piccart, M.J., de Valeriola, D., Dal Lago, L., de Azambuja, E., Demonty, G., Lebrun, F., Bernard-Marty, Ch, Colozza, M., Cufer, T.

“…The 2003 St. Gallen consensus panel divided the many available adjuvant chemotherapy (CT) regimens into those with “standard efficacy” (AC×4, CMF×6) and those…”
Get full text

Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: Real-world insights from practicing European physicians by Rider, A., Seesaghur, A., Lewis, K., Bluff, D., Marongiu, A., Demonty, G.

Get full text

1792P - Adherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: Real-world insights from practicing European physicians by Rider, A., Seesaghur, A., Lewis, K., Bluff, D., Marongiu, A., Demonty, G.

“…Despite existing clinical guidelines on bone health in patients with cancer (ESMO 2014), the use of recommended BTA is sub-optimal for many patients. It is…”
Get full text

1792PAdherence to ESMO 2014 guidelines on bone-targeting agent (BTA) initiation for breast and prostate cancer patients: Real-world insights from practicing European physicians by Rider, A, Seesaghur, A, Lewis, K, Bluff, D, Marongiu, A, Demonty, G

“…Abstract Background Despite existing clinical guidelines on bone health in patients with cancer (ESMO 2014), the use of recommended BTA is sub-optimal for many…”
Get full text

Current status of the EORTC 10981–22023 AMAROS trial – After mapping of the axilla radiotherapy or surgery by Straver, M, Meijnen, P, van Tienhoven, G, van Velde, C.J.H, Mansel, R.E, Bogaerts, J, Demonty, G, Nossent, R, Duez, N, Rutgers, E.J.T.H

Get full text

866 Management of bone metastases secondary to prostate cancer: A comprehensive survey of practice patterns in five European countries by Lebret, T, Flinois, A, Schoen, P, Shepherd, S, Demonty, G

Get full text

Outcomes in patients receiving maintenance therapy in two panitumumab (Pmab) first-line trials for metastatic colorectal cancer (mCRC) by Rivera Herrero, F., Bachet, J-B., Modest, D.P., de Braud, F., Pietrantonio, F., Koukakis, R., Demonty, G., Douillard, J-Y.

Get full text

PD-031 An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials by Rivera, F., Karthaus, M., Valladares-Ayerbes, M., Gallego, J., Koukakis, R., Demonty, G., Douillard, J.-Y.

Get full text

Importance of tumour symptoms and extent of disease on efficacy of first-line FOLFOX4 ± panitumumab (pmab) in patients (pts) with RAS wild-type (WT)/BRAF WT metastatic colorectal cancer (mCRC) in the PRIME study by Taieb, J., Peeters, M., Siena, S., Herrero, F. Rivera, Koukakis, R., Demonty, G., Douillard, J.-Y.

Get full text

Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab + FOLFOX4 vs FOLFOX4 by Siena, S., Herrero, F. Rivera, Douillard, J.-Y., Taieb, J., Koukakis, R., Demonty, G., Peeters, M.

Get full text